The US-based Forest Laboratories has entered into a settlement agreement with Glenmark Generics Inc USA, in a patent infringement litigation at the US court.
Forest had filed suit against Glenmark, which sought approval with USFDA to market generic versions of Forest's hypertension drug - Bystolic (nebivolol) tablets.
Under the terms of the settlement agreement, Forest will provide a licence to Glenmark that will permit it to launch its generic versions of Bystolic by three months prior to the expiration of US Patent or the date Glenmark receives final FDA approval of its ANDA.
Forest had settled similar patent infringement suits with Indian companies such as Hetero Labs, Alkem Laboratories, Indchemie Health Specialties and Torrent Pharmaceuticals. Bystolic, a once-daily treatment for the treatment of high blood pressure, was introduced in the US in 2008.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.